Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. Blood Adv 2017 Aug 22;1(19):1533-1536

Date

01/04/2018

Pubmed ID

29296794

Pubmed Central ID

PMC5728466

DOI

10.1182/bloodadvances.2017007526

Scopus ID

2-s2.0-85040141428

Abstract

Optimal salvage therapy for refractory HLH is unknown.In our patient, ruxolitinib treatment led to clinical remission of refractory HLH.

Author List

Broglie L, Pommert L, Rao S, Thakar M, Phelan R, Margolis D, Talano J

Authors

Larisa Broglie MD, MS Assistant Professor in the Pediatrics department at Medical College of Wisconsin
David A. Margolis MD Interim Chair, Professor in the Pediatrics department at Medical College of Wisconsin
Rachel A. Phelan MD Assistant Professor in the Pediatrics department at Medical College of Wisconsin
Sridhar Rao MD, PhD Associate Professor in the Pediatrics department at Medical College of Wisconsin
Julie-An M. Talano MD Professor in the Pediatrics department at Medical College of Wisconsin